@article{LepetaLourencoSchweitzeretal.2016,
  author    = {Lepeta, Katarzyna and Lourenco, Mychael V. and Schweitzer, Barbara C. and Martino Adami, Pamela V. and Banerjee, Priyanjalee and Catuara-Solarz, Silvina and de la Fuente Revenga, Mario and Marc Guillem, Alain and Haider, Mouna and Ijomone, Omamuyovwi M. and Nadorp, Bettina and Qi, Lin and Perera, Nirma D. and Refsgaard, Louise K. and Reid, Kimberley M. and Sabbar, Mariam and Sahoo, Arghyadip and Schaefer, Natascha and Sheean, Rebecca K. and Suska, Anna and Verma, Rajkumar and Vicidomini, Cinzia and Wright, Dean and Zhang, Xing-Ding and Seidenbecher, Constanze},
  title     = {Synaptopathies: synaptic dysfunction in neurological disorders - a review from students to students},
  series = {Journal of Neurochemistry},
  volume    = {138},
  journal   = {Journal of Neurochemistry},
  number    = {6},
  doi       = {10.1111/jnc.13713},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-187509},
  pages     = {785-805},
  year      = {2016},
  abstract  = {Synapses are essential components of neurons and allow information to travel coordinately throughout the nervous system to adjust behavior to environmental stimuli and to control body functions, memories, and emotions. Thus, optimal synaptic communication is required for proper brain physiology, and slight perturbations of synapse function can lead to brain disorders. In fact, increasing evidence has demonstrated the relevance of synapse dysfunction as a major determinant of many neurological diseases. This notion has led to the concept of synaptopathies as brain diseases with synapse defects as shared pathogenic features. In this review, which was initiated at the 13th International Society for Neurochemistry Advanced School, we discuss basic concepts of synapse structure and function, and provide a critical view of how aberrant synapse physiology may contribute to neurodevelopmental disorders (autism, Down syndrome, startle disease, and epilepsy) as well as neurodegenerative disorders (Alzheimer and Parkinson disease). We finally discuss the appropriateness and potential implications of gathering synapse diseases under a single term. Understanding common causes and intrinsic differences in disease-associated synaptic dysfunction could offer novel clues toward synapse-based therapeutic intervention for neurological and neuropsychiatric disorders. In this Review, which was initiated at the 13th International Society for Neurochemistry (ISN) Advanced School, we discuss basic concepts of synapse structure and function, and provide a critical view of how aberrant synapse physiology may contribute to neurodevelopmental (autism, Down syndrome, startle disease, and epilepsy) as well as neurodegenerative disorders (Alzheimer's and Parkinson's diseases), gathered together under the term of synaptopathies. Read the Editorial Highlight for this article on page .},
  language  = {en}
}
@article{ElHajjDittrichBoecketal.2016,
  author    = {El Hajj, Nady and Dittrich, Marcus and B{\"o}ck, Julia and Kraus, Theo F. J. and Nanda, Indrajit and M{\"u}ller, Tobias and Seidmann, Larissa and Tralau, Tim and Galetzka, Danuta and Schneider, Eberhard and Haaf, Thomas},
  title     = {Epigenetic dysregulation in the developing Down syndrome cortex},
  series = {Epigenetics},
  volume    = {11},
  journal   = {Epigenetics},
  number    = {8},
  doi       = {10.1080/15592294.2016.1192736},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-191239},
  pages     = {563-578},
  year      = {2016},
  abstract  = {Using Illumina 450K arrays, 1.85\% of all analyzed CpG sites were significantly hypermethylated and 0.31\% hypomethylated in fetal Down syndrome (DS) cortex throughout the genome. The methylation changes on chromosome 21 appeared to be balanced between hypo- and hyper-methylation, whereas, consistent with prior reports, all other chromosomes showed 3-11times more hyper- than hypo-methylated sites. Reduced NRSF/REST expression due to upregulation of DYRK1A (on chromosome 21q22.13) and methylation of REST binding sites during early developmental stages may contribute to this genome-wide excess of hypermethylated sites. Upregulation of DNMT3L (on chromosome 21q22.4) could lead to de novo methylation in neuroprogenitors, which then persists in the fetal DS brain where DNMT3A and DNMT3B become downregulated. The vast majority of differentially methylated promoters and genes was hypermethylated in DS and located outside chromosome 21, including the protocadherin gamma (PCDHG) cluster on chromosome 5q31, which is crucial for neural circuit formation in the developing brain. Bisulfite pyrosequencing and targeted RNA sequencing showed that several genes of PCDHG subfamilies A and B are hypermethylated and transcriptionally downregulated in fetal DS cortex. Decreased PCDHG expression is expected to reduce dendrite arborization and growth in cortical neurons. Since constitutive hypermethylation of PCDHG and other genes affects multiple tissues, including blood, it may provide useful biomarkers for DS brain development and pharmacologic targets for therapeutic interventions.},
  language  = {en}
}